Good morning. New coronavirus cases are declining in countries with high vaccination rates. Then there is Europe.
Europe’s vaccine messIt is the latest sign of the power of the Covid-19 vaccines: The number of new cases is declining, often sharply, in countries that have vaccinated a large share of residents. That’s the situation in Israel, the United Arab Emirates and Britain. Cases are also declining in the U.S., which is not as far along as those three countries but is well ahead of most. And on the other end of the spectrum is the European continent.
Across most of the European Union, vaccine rollout has been slow, and new cases are surging. Europe — the first place where the coronavirus caused widespread death — is facing the prospect of being one of the last places to emerge from its grip. My colleague Jason Horowitz writes from Rome: “Governments are putting exhausted populations under lockdown. Street protests are turning violent. A year after the virus began spreading in Europe, things feel unnervingly the same.” As Eyck Freymann and Elettra Ardissino write in Foreign Policy: “Spring in the European Union is going to be dismal.” Bild, a German newspaper, recently ran the headline “Liebe Briten, We Beneiden You!” — a mixture of German and English that means “Dear Brits, We Envy You!” Wolfgang Münchau of Eurointelligence has said that Europe’s vaccination program rivals the continent’s budget austerity of recent years as “the E.U.’s worst policy error during my lifetime.” Why has Europe done so poorly? There are three main reasons. 1. Too much bureaucracyWhile the U.S. and other countries rushed to sign agreements with vaccine makers, the E.U. first tried to make sure all 27 of its member countries agreed on how to approach the negotiations. Europe chose “to prioritize process over speed and to put solidarity between E.U. countries ahead of giving individual governments more room to maneuver,” Jillian Deutsch and Sarah Wheaton write for Politico Europe. The result was slower regulatory approval of the vaccines and delayed agreements to buy doses, forcing Europe to wait in line behind countries that moved faster. 2. Penny-wise and pound-foolish
Europe put a big emphasis on negotiating a low price for vaccine doses. Israeli officials, by contrast, were willing to pay a premium to receive doses quickly. Israel has paid around $25 per Pfizer dose, and the U.S. pays about $20 per dose. The E.U. pays from $15 to $19. The discounted price became another reason that Europe had to wait in line behind other countries. Even in purely economic terms, the trade-off will probably be a bad one: Each $1 saved per vaccine dose might ultimately add up to $1 billion — a rounding error in a trading bloc with a nearly $20 trillion annual economic output. A single additional lockdown, like the one Italy announced this week, could wipe out any savings. “The price difference is macroeconomically irrelevant,” Münchau writes. The E.U. “tried to lock in a perceived short-term price advantage at the expense of everything else.” 3. Vaccine skepticism“Europe is the world’s epicenter of vaccine skepticism,” Deutsch and Wheaton of Politico Europe write. That skepticism predated Covid, and now its consequences are becoming clear. In a survey published in the journal Nature Medicine, residents of 19 countries were asked if they would take a Covid vaccine that had been “proven safe and effective.” In China, 89 percent of people said yes. In the U.S., 75 percent did. The shares were lower across most of Europe: 68 percent in Germany, 65 percent in Sweden, 59 percent in France and 56 percent in Poland.
The skepticism helps explain Europe’s latest vaccination problem. About a dozen countries, including France and Germany, have suspended the use of one of the continent’s primary vaccines, from AstraZeneca, citing concerns about blood clots. But the evidence that the vaccine causes clots is thin. Europe’s main drug regulator still says the benefits outweigh the risks. And Ann Taylor, AstraZeneca’s chief medical officer, has pointed out that the rate of clotting among vaccinated Europeans is lower than “would be expected among the general population.” Dr. Muge Cevik, a virus expert at the University of St. Andrews, told me yesterday that it was always important to scrutinize vaccines. But, she added, “I would say the benefits of the A.Z. vaccine in preventing Covid, hospitalization and death outweigh the risks of side effects, especially in the middle of the pandemic.” The bottom line: Over the summer, the U.S. was struggling more than any other country to contain Covid. Today, Europe appears to be in much worse shape.
The Virus
U.S. News
Other Big Stories
Opinions A recent New Yorker essay by Jelani Cobb has spurred a debate: Is the Republican Party endangered?
Morning Reads
Lake Baikal: Usually it’s foreigners who cavort at the world’s deepest lake. This winter, it’s Russians. Lives Lived: Nicknamed the Queen of Dreams, Dr. Rosalind D. Cartwright studied the role of dreaming in divorce-induced depression, worked with sleep apnea patients and helped open one of the first sleep disorder clinics. She died at 98.
More than a century of the Book ReviewAs The New York Times Book Review turns 125, you can comb through a timeline of some of the most significant moments in its history, including:
What to Cook
This salmon and couscous salad is a quick weeknight dish. Awards Season “Mank” leads the Oscar nominations. And for the first time, two women are nominated for best director: Emerald Fennell (for “Promising Young Woman”) and Chloé Zhao (for “Nomadland”). Here’s a list of snubs and surprises. Virtual Travel See the breathtaking landscapes of the Fagaras Mountains in Romania. Late Night The hosts discussed Gov. Andrew Cuomo. Now Time to Play
The pangram from yesterday’s Spelling Bee was emolument. Here is today’s puzzle — or you can play online. Here’s today’s Mini Crossword, and a clue: Roll with a hole (five letters). If you’re in the mood to play more, find all our games here. Thanks for spending part of your morning with The Times. See you tomorrow. — David P.S. Eleanor Lutz, the newest full-time editor on The Times’s graphics desk, has a Ph.D. in biology and data science. Correction: Yesterday’s newsletter misstated the effect of Covid on the Juma people in the Amazon. The virus killed the last living Juma male, who was the only fluent speaker of the tribe’s language. He was not the last member of the tribe. You can see today’s print front page here. Today’s episode of “The Daily” is about wind energy. On the latest “Popcast,” how TikTok is reshaping pop. Lalena Fisher, Claire Moses, Ian Prasad Philbrick, Tom Wright-Piersanti and Sanam Yar contributed to The Morning. You can reach the team at themorning@nytimes.com. Sign up here to get this newsletter in your inbox.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
